

Funder	Project Title	Funding	Strategic Plan Objective	Institution
Autism Speaks	Acamprosate in Youth with Autism Spectrum Disorders	\$0	4.1	Cincinnati Children's Hospital Medical Center
National Institutes of Health	ACE Center: Augmenting language interventions for ASD: A translational approach	\$278,494	4.1	University of California, Los Angeles
Health Resources and Services Administration	A Controlled Trial of Sertraline in Young Children with ASD	\$300,000	4.1	University of California, Davis
National Institutes of Health	A drug-screening platform for autism spectrum disorders using human neurons and astrocytes	\$37,474	4.1	National Institutes of Health
Organization for Autism Research	An Interdisciplinary Approach to the Treatment of Encopresis in Children with Autism Spectrum Disorder	\$0	4.1	Marcus Autism Center
Department of Defense - Army	A randomized, controlled trial of intranasal oxytocin as an adjunct to behavioral therapy for autism spectrum disorder	\$0	4.1	Massachusetts General Hospital
Autism Science Foundation	A Unified Molecular Mechanism Explaining Social Behavior and Oxytocin levels in ASD	\$0	4.1	Washington University in St. Louis
National Institutes of Health	Behavioral and Neural Response to Memantine in Adolescents with Autism	\$186,192	4.1	Massachusetts General Hospital
Department of Defense - Army	Cannabidiol (CBD) Versus Placebo in Children with Autism Spectrum Disorder (ASD)	\$1,267,800	4.1	Albert Einstein College of Medicine
Simons Foundation	Clinical Research Associates	\$1,750,000	4.1	Clinical Research Associates
Autism Research Institute	Clinical Trial of Suramin to Treat Autism	\$230,000	4.1	University of California, San Diego Medical Center
Health Resources and Services Administration	Clonidine for Sleep Disturbance in Children with ASD	\$0	4.1	Nationwide Children's Hospital
Autism Science Foundation	Combined Effects of Early Behavioral Intervention and Propranolol on ASD	\$0	4.1	University of Missouri
Simons Foundation	Deep Brain Stimulation for Autistic Self-Injurious Behavior	\$0	4.1	Johns Hopkins University
National Institutes of Health	Development of PDE2 Inhibitors for Treatment of Anxiety/Depression in Autism/Schizophrenia	\$348,094	4.1	Intra-Cellular Therapies, Inc.
National Institutes of Health	Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders	\$662,214	4.1	Saint Louis University
Brain & Behavior Research Foundation	Enhancing Social Learning Through Oxytocin Augmentation of Social Skills Groups in Children with ASD	\$65,000	4.1	Rush University
Simons Foundation	Evaluation of a melanocortin agonist to improve social cognition in autism	\$139,606	4.1	University of Sydney
Autism Speaks	Identifying Genetic and Epigenetic Signatures of Treatment Response to Oxytocin in Humans and Mice	\$30,400	4.1	Duke University

Funder	Project Title	Funding	Strategic Plan Objective	Institution
National Institutes of Health	Integrated treatments for core deficits in autism spectrum disorder	\$124,638	4.1	Rush University Medical Center
Department of Defense - Army	Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD)	\$0	4.1	Holland Bloorview Kids Rehabilitation Hospital
Department of Defense - Army	Metabolic signature of antipsychotics used in the treatment of autism	\$0	4.1	University of Cincinnati
Autism Research Institute	Mitochondrial Dysfunction Associated with Autism: Clinical Signals and Treatment Outcomes	\$20,000	4.1	Boston University
Department of Defense - Army	Neurosteroids Reverse Tonic Inhibition Deficits in Fragile X Syndrome	\$0	4.1	Tufts University School of Medicine
Department of Defense - Army	Neurosteroids Reverse Tonic Inhibition Deficits in Fragile X Syndrome	\$0	4.1	Tufts University School of Medicine
Autism Speaks	Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism	\$0	4.1	Yale University
Simons Foundation	Optimizing social effects of oxytocin with opioid blocker	\$0	4.1	Yale University
National Institutes of Health	Postnatal combination therapy for cerebral palsy	\$331,667	4.1	Johns Hopkins University
National Institutes of Health	Preventing Epilepsy using Vigabatrin in Infants with Tuberous Sclerosis Complex	\$1,488,631	4.1	University of Alabama At Birmingham
Simons Foundation	Randomized Controlled Pilot Trial of Pregnenolone in Autism	\$125,000	4.1	Stanford University
Autism Speaks	Response Heterogeneity to GI Treatment, Autism Symptom and Improved Oxidative Stress	\$188,901	4.1	Children's Hospital Los Angeles
Simons Foundation	Safety, Efficacy and Basis of Oxytocin and Brain Stimulation Therapy in ASD	\$261,261	4.1	University of Pennsylvania
National Institutes of Health	Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B)	\$1,708,646	4.1	Duke University
National Institutes of Health	The Effects of Intranasal Oxytocin on Social Cognition and Neural Activity	\$376,057	4.1	Emory University
Autism Science Foundation	The Effects of Oxytocin on Functional Neural Connectivity in Autism	\$0	4.1	University of North Carolina at Chapel Hill
Department of Defense - Army	Trial of Propranolol in Children and Youth with ASD and Predictors of Response	\$0	4.1	University of Missouri

